Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

被引：18

作者：

Liu, Yufei ^{[1
]}

Zhang, Zhe ^{[2
]}

Rinsurongkawong, Waree ^{[3
]}

Gay, Carl M. ^{[4
]}

Le, Xiuning ^{[4
]}

Ning, Matthew S. ^{[1
]}

Lewis, Jeff ^{[3
]}

Rinsurongkawong, Vadeerat ^{[3
]}

Lee, J. Jack ^{[3
]}

Roth, Jack ^{[5
]}

Swisher, Stephen ^{[5
]}

Gandhi, Saumil ^{[1
]}

Lee, Percy P. ^{[1
]}

Gibbons, Don L. ^{[1
]}

Vaporciyan, Ara A. ^{[5
]}

Heymach, John, V ^{[4
]}

Zhang, Jianjun ^{[4
]}

Lin, Steven H. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 6565 MD Anderson Blvd,Z7-5044, Houston, TX 77030 USA

[2] Rice Univ, Dept Sociol, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiothorac Surg, Houston, TX 77030 USA

来源：

JAMA NETWORK OPEN | 2022年 / 5卷 / 06期

关键词：

NSCLC; OSIMERTINIB; SURVIVAL; BLOCKADE; UPDATE;

D O I：

10.1001/jamanetworkopen.2022.15589

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IMPORTANCE Consolidative durvalumab after definitive chemoradiation for unresectable locally advanced non-small cell lung cancer (NSCLC) can significantly improve progression-free survival (PFS) and overall survival (OS), as shown in the PACIFIC trial. However, whether patients with driver variations derive equal benefit from this regimen remains unclear. OBJECTIVES To compare outcomes of patients with locally advanced NSCLC with and without driver variations treated with the PACIFIC regimen. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined 104 patients with unresectable locally advanced NSCLC with mutational profiling treated at a tertiary cancer center with definitive chemoradiation and consolidative durvalumab from June 2017 through May 2020. Patients with recurrent disease or those receiving postoperative therapy were excluded. Outcomes were analyzed with Kaplan-Meier and multivariate regression analyses. EXPOSURES Patients were grouped according to the presence of non-KRAS driver variations (EGFR exon 19 deletion, EGFR exon 20 insertion, EGFR exon 21 mutation [L858 R], ER882 exon 20 insertion, EML4-ALK fusion, MET exon 14 skipping, NTRK2 fusion), KRAS driver variations, or no driver variations. MAIN OUTCOMES AND MEASURES The primary outcomes were PFS, OS, and second progression-free survival (PFS2) times. RESULTS The 104 patients had a median (I QR) age of 65.1(9.8) years, with 55 females (53%) and 85 former or current smokers (88%). There were 43 patients (41%) with driver variations with a median PFS time of 8.4 months vs 40.1 months for patients without driver variations (hazard ratio [Fin 2.75; 95% CI, 1.64-4.62; log-rank P < .001). Both patients with non-KRAS and KRAS driver variations had worse PFS. No difference in OS was found between patients with and without driver variations (log rank P = .24). Among the 63 patients who developed progressive disease, those with non-KRAS driver variations had a median PFS2 time of 13.7 months vs 4.4 months for all other patients (HR, 0.37; 95% CI, 0.21-0.64; log-rank P = .001). Rates of overall grade 2 toxic effects or higher did not differ by driver mutation status. CONCLUSIONS AND RELEVANCE In this cohort study, driver variations in patients with unresectable locally advanced NSCLC were associated with significantly shorter PFS time after definitive chemoradiation and consolidative durvalumab. These findings suggest the need to consider additional or alternative treatment options to the PACIFIC regimen for patients with driver variations.

引用

页数：10

共 18 条

[1] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[2] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy [J].

Aredo, Jacqueline V. ;

Mambetsariev, Isa ;

Hellyer, Jessica A. ;

Amini, Arya ;

Neal, Joel W. ;

Padda, Sukhmani K. ;

McCoach, Caroline E. ;

Riess, Jonathan W. ;

Cabebe, Elwyn C. ;

Naidoo, Jarushka ;

Abuali, Tariq ;

Salgia, Ravi ;

Loo Jr, Billy W. ;

Diehn, Maximilian ;

Han, Summer S. ;

Wakelee, Heather A. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) :1030-1041

[3] The Eighth Edition Lung Cancer Stage Classification [J].

Detterbeck, Frank C. ;

Boffa, Daniel J. ;

Kim, Anthony W. ;

Tanoue, Lynn T. .

CHEST, 2017, 151 (01) :193-203

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial [J].

Faivre-Finn, Corinne ;

Vicente, David ;

Kurata, Takayasu ;

Planchard, David ;

Paz-Ares, Luis ;

Vansteenkiste, Johan F. ;

Spigel, David R. ;

Garassino, Marina C. ;

Reck, Martin ;

Senan, Suresh ;

Naidoo, Jarushka ;

Rimner, Andreas ;

Wu, Yi-Long ;

Gray, Jhanelle E. ;

Ozguroglu, Mustafa ;

Lee, Ki H. ;

Cho, Byoung C. ;

Kato, Terufumi ;

de Wit, Maike ;

Newton, Michael ;

Wang, Lu ;

Thiyagarajah, Piruntha ;

Antonia, Scott J. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) :860-867

[6] Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study [J].

Garassino, Marina Chiara ;

Cho, Byoung-Chul ;

Kim, Joo-Hang ;

Mazieres, Julien ;

Vansteenkiste, Johan ;

Lena, Herve ;

Jaime, Jesus Corral ;

Gray, Jhanelle E. ;

Powderly, John ;

Chouaid, Christos ;

Bidoli, Paolo ;

Wheatley-Price, Paul ;

Park, Keunchil ;

Soo, Ross A. ;

Poole, Lynne ;

Wadsworth, Catherine ;

Dennis, Phillip A. ;

Rizvi, Naiyer A. .

LUNG CANCER, 2020, 147 :137-142

[7] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[8] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors [J].

Hong, David S. ;

Fakih, Marwan G. ;

Strickler, John H. ;

Desai, Jayesh ;

Durm, Gregory A. ;

Shapiro, Geoffrey I. ;

Falchook, Gerald S. ;

Price, Timothy J. ;

Sacher, Adrian ;

Denlinger, Crystal S. ;

Bang, Yung-Jue ;

Dy, Grace K. ;

Krauss, John C. ;

Kuboki, Yasutoshi ;

Kuo, James C. ;

Coveler, Andrew L. ;

Park, Keunchil ;

Kim, Tae Won ;

Barlesi, Fabrice ;

Munster, Pamela N. ;

Ramalingam, Suresh S. ;

Burns, Timothy F. ;

Meric-Bernstam, Funda ;

Henary, Haby ;

Ngang, Jude ;

Ngarmchamnanrith, Gataree ;

Kim, June ;

Houk, Brett E. ;

Canon, Jude ;

Lipford, J. Russell ;

Friberg, Gregory ;

Lito, Piro ;

Govindan, Ramaswamy ;

Li, Bob T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13) :1207-1217

[9] Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress [J].

Lu, Shun ;

Casarini, Ignacio ;

Kato, Terufumi ;

Cobo, Manuel ;

Ozguroglu, Mustafa ;

Hodge, Rachel ;

van der Gronde, Toon ;

Saggese, Matilde ;

Ramalingam, Suresh S. .

CLINICAL LUNG CANCER, 2021, 22 (04) :371-375

[10] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry [J].

Mazieres, J. ;

Drilon, A. ;

Lusque, A. ;

Mhanna, L. ;

Cortot, A. B. ;

Mezquita, L. ;

Thai, A. A. ;

Mascaux, C. ;

Couraud, S. ;

Veillon, R. ;

Van Den Heuvel, M. ;

Neal, J. ;

Peled, N. ;

Fruh, M. ;

Ng, T. L. ;

Gounant, V ;

Popat, S. ;

Diebold, J. ;

Sabari, J. ;

Zhu, V. W. ;

Rothschild, S. I. ;

Bironzo, P. ;

Martinez-Marti, A. ;

Curioni-Fontecedro, A. ;

Rosell, R. ;

Lattuca-Truc, M. ;

Wiesweg, M. ;

Besse, B. ;

Solomon, B. ;

Barlesi, F. ;

Schouten, R. D. ;

Wakelee, H. ;

Camidge, D. R. ;

Zalcman, G. ;

Novello, S. ;

Ou, S. I. ;

Milia, J. ;

Gautschi, O. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1321-1328

← 1 2 →